COMP <GO>
UTHR vs ALNY // EV/EBITDA & P/E VALUATION
United Therapeutics Corporation (NASDAQ) VS. Alnylam Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: UTHR 10
— ALNY 3
▲ EV/EBITDA & P/E VALUATION LEADER: UTHR
LAST: $596.13 (-0.43%) • MKT CAP: $25.68B
valuation
12.5x
LAST: $158.00 (-4.24%) • MKT CAP: $22.10B
valuation
42.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UTHR VS. ALNY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UTHR | ALNY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.90% | 81.80% | +6.10 | UTHR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.10% | 21.30% | -1.20 | ALNY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 12.5x | 42.4x | -29.90 | UTHR | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | 2.00% | +2.09 | UTHR | /fcf-yield <GO> |
| Operating Margin | 46.90% | 13.50% | +33.40 | UTHR | /operating-margins <GO> |
| Net Profit Margin | 41.90% | 8.40% | +33.50 | UTHR | /net-margins <GO> |
| Revenue Growth (YoY) | 10.60% | 65.20% | -54.60 | ALNY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 22.52 | 3.16 | +19.36 | UTHR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | UTHR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.6 | 25.8 | +42.80 | UTHR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.00 | -0.05 | ALNY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.8x | 62.3x | -44.50 | UTHR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $25.68B | $22.10B | $3.58B | UTHR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UTHR REV | ALNY REV | UTHR GROSS % | ALNY GROSS % | UTHR FCF | ALNY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.18B | $3.71B | 87.9% | 81.8% | $1.04B | $465.4M |
| FY 2024 | $2.88B | $2.25B | 89.2% | 86.4% | $1.08B | -$42.6M |
| FY 2023 | $2.33B | $1.83B | — | — | $873.3M | $21.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UTHR // BETA 0.95
ALNY // BETA 1.00